Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Aurobac Therapeutics General Information
Lead asset ATX101 has shown promising preclinical data targeting vascular integrity loss in septic shock. The company’s pipeline includes multiple preclinical/discovery programs against Gram-negative pathogens. No clinical results yet as first-in-human studies are planned for the near future.
Contact Information
Drug Pipeline
ATX101
Phase 1Key Partnerships
Boehringer Ingelheim, Evotec SE, bioMérieux SA, Ongoing collaborations on diagnostics and therapeutics development
Aurobac Therapeutics Funding
No funding data available
To view Aurobac Therapeutics's complete valuation and funding history, request access »